What were the key financial results for Regeneron in Q2 2013?

The 8-K filing itself does not contain specific financial figures, but it states that Regeneron issued a press release on August 6, 2013, detailing its financial and operating results for the quarter ended June 30, 2013. Investors should refer to Exhibit 99.1 for the detailed financial results.

What is the significance of the EYLEA® Phase 3 trial results for Diabetic Macular Edema (DME)?

The announcement of positive one-year top-line results from two Phase 3 trials is highly significant as it demonstrates the efficacy of EYLEA® in treating DME. This opens up a substantial new market for EYLEA®, potentially leading to significant revenue growth.

When can investors expect EYLEA® to be approved for Diabetic Macular Edema?

Regeneron, in partnership with Bayer HealthCare, expects to submit applications for regulatory approval of EYLEA® for Diabetic Macular Edema in the United States and Europe during 2013.

Are the results of the press releases considered 'filed' with the SEC?

The filing explicitly states that the information included or incorporated from the press releases (Item 2.02 and Exhibit 99.1) shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference in any Securities Act filing, unless expressly set forth by specific reference in such a filing.

REGN 8-K: Earnings & Results

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 6, 2013, to report its financial and operating results for the second quarter ended June 30, 2013. While specific financial figures are not detailed in the 8-K itself, they are referenced in an accompanying press release (Exhibit 99.1). This filing also announced significant positive developments for EYLEA® (aflibercept), specifically one-year top-line results from two Phase 3 trials in Diabetic Macular Edema (DME). These positive results are a key driver for potential future growth, with regulatory submissions anticipated in the U.S. and Europe later in 2013.

Key Highlights

1Regeneron reported its second quarter 2013 financial and operating results via press release.
2Significant positive one-year top-line results were announced from two Phase 3 trials for EYLEA® (aflibercept) in Diabetic Macular Edema (DME).
3This positive DME data represents a substantial expansion opportunity for EYLEA®.
4Regulatory submissions for EYLEA® in DME are planned for the United States and Europe in 2013.
5The company is progressing with EYLEA® development and regulatory pathways for this new indication.
6This announcement suggests strong potential for increased EYLEA® sales and market penetration.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Aug 6, 2013)

Summary

Key Highlights

Frequently Asked Questions